Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.58 |
| ▸ | PLK4 | O00444 | 1/20 | 0.56 |
| ▸ | JAK2 | O60674 | 8/20 | 0.55 |
| ▸ | JAK3 | P52333 | 6/20 | 0.55 |
| ▸ | JAK1 | P23458 | 3/20 | 0.53 |
| ▸ | AURKA | O14965 | 2/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.51 |
| ▸ | TYK2 | P29597 | 2/20 | 0.51 |
| ▸ | IGF1R | P08069 | 4/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18559719 | 1.00 | EGFR (0.58) | EGFRPLK4JAK2JAK3JAK1 | |
| SCHEMBL13859327 | 1.00 | EGFR (0.58) | EGFRPLK4JAK2JAK3JAK1 | |
| SCHEMBL18559720 | 0.91 | EGFR (0.62) | EGFRPLK4JAK2JAK3JAK1 | |
| SCHEMBL16204478 | 0.91 | EGFR (0.62) | EGFRPLK4JAK2JAK3JAK1 | |
| SCHEMBL13859528 | 0.88 | AURKA (0.50) | EGFRPLK4JAK2JAK3AURKA | |
| SCHEMBL13859526 | 0.88 | AURKA (0.50) | EGFRPLK4JAK2JAK3AURKA | |
| SCHEMBL13977853 | 0.84 | PLK4 (0.60) | EGFRPLK4JAK2JAK3JAK1 | |
| SCHEMBL13859449 | 0.81 | JAK3 (0.77) | EGFRPLK4JAK2JAK3JAK1 | |
| SCHEMBL13859349 | 0.77 | ABL1 (0.52) | JAK2JAK3MAPK8 | |
| SCHEMBL13859348 | 0.77 | ABL1 (0.52) | JAK2JAK3MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580427-B2 | Kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580427-B2 | Kinase inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-28 | — | — | US | disclosed |
| US-20140323464-A1 | KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-30 | — | — | US | disclosed |
| US-20140323464-A1 | KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-30 | — | — | US | disclosed |
| EP-2710007-A2 | KINASE INHIBITORS | The Regents of the University of California (US) | 2014-03-26 | — | — | EP | disclosed |
| WO-2012158843-A2 | KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323464-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | EGFR 432/4885PLK4 313/4885JAK2 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.